Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers

核心3总结/摘要 核心3支持本PPG中的临床导向转化研究。在这份更新申请中，所有 这三个项目共同关注GI GVHD。Core 3开发了新的服务 因此，我们需要与GI GVHD相关的研究，以满足所有三个项目的这一日益增加的关注。第一个创建一个 为人类和小鼠样本提供统一的胃肠道病理学核心，并为所有三个项目提供服务。 这些中央病理学服务提供跨物种分析的连续性，确保 项目1和项目2中的机制研究尽可能与人体样本分析密切相关 在项目3中。 第二项新服务创建了一个多中心临床数据库和存储库， 以前的单中心数据库和存储库。我们召集了一个由八个主要的 移植中心（美国有四个：密歇根大学、俄亥俄州州立大学、马约诊所和 宾夕法尼亚大学;德国有四所：里根斯堡、德累斯顿、汉堡和维尔茨堡）。我们 一个名为MAGIC（密歇根急性GVHD国际联盟）的新联盟将加速 通过整合来自800多例同种异体BMT的临床和实验室结果进行GVHD研究 每年的获奖者生物样本与来自多个地点的详细临床数据的联系有助于 确保我们的分析和临床试验结果将在整个BMT社区推广。 这一核心的第三项新服务是在上一个周期的主要成就的基础上建立的， 开发了第一个经验证的基于GVHD生物标志物的分级系统（安阿伯GVHD分级）。 核心3将进行ELISA检测，包括（对于美国中心）真实的安阿伯分级， 这是确定项目3中实验性GVHD临床治疗试验合格患者所需的。 核心3支持本PPG中的转化研究。在这份更新申请中，所有三个项目 分享对GI GVHD的综合、协同关注。Core 3开发了与GI相关的新服务 GVHD，以满足这三个项目的重点增加。第一种方法创建了一个统一的GI 人类和小鼠样本的病理学核心，并为所有三个项目提供服务。这些中央 病理学服务提供跨物种分析的连续性，确保机制研究 项目1和2中的分析尽可能与项目3中的人体样本分析密切相关

CORE 3 SUMMARY/ABSTRACT Core 3 supports the clinically oriented translational studies in this PPG. In this renewal application, all three projects share an integrated, synergistic focus on GI GVHD. Core 3 has developed new services related to GI GVHD in order to meet this increased focus of all three projects. The first creates a consolidated GI pathology core for both human and mouse samples and services all three projects. These central pathology services provide continuity of analyses across species, ensuring that the mechanistic studies in Projects 1 and 2 relate as closely as possible to the analysis of human samples in Project 3. The second new service creates a multi-center clinical database and repository, significantly expanding the previous single center database and repository. We have assembled a consortium of eight major transplant centers (four in the USA: University of Michigan, Ohio State University, Mayo Clinic, and University of Pennsylvania; and four in Germany: Regensburg, Dresden, Hamburg, and Würzburg). Our new consortium, called MAGIC (Michigan Acute GVHD International Consortium), will accelerate research in GVHD by integrating clinical and laboratory findings from more than 800 allogeneic BMT recipients annually. The linkage of biologic samples with detailed clinical data from multiple sites helps ensure that our analyses and clinical trial results will be generalizable throughout the BMT community. The third new service of this core builds upon the major accomplishment from the last cycle, the development of the first validated GVHD biomarker-based grading system (Ann Arbor GVHD Grading). Core 3 will perform the ELISA assays, including (for US centers) the real time Ann Arbor grading, which is needed to identify eligible patients for experimental GVHD clinical treatment trial in Project 3. Core 3 supports the translational studies in this PPG. In this renewal application, all three projects share an integrated, synergistic focus on GI GVHD. Core 3 has developed new services related to GI GVHD in order to meet this increased focus of all three projects. The first creates a consolidated GI pathology core for both human and mouse samples and services all three projects. These central pathology services provide continuity of analyses across species, ensuring that the mechanistic studies in Projects 1 and 2 relate as closely as possible to the analysis of human samples in Project 3